More than a dozen companies have shifted their focus toward the development of HR-positive/HER2-negative breast cancer drugs. Some of them are Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others. The primary goal of early HR+/HER2- breast cancer therapy is to enhance disease-free survival and overall survival with current treatments while minimizing long-term side effects. Advances in local therapies, such as breast-conserving surgery, sentinel lymph node biopsy...
